Amir A. Jazaeri MD FACS, FACOG
Gynecologic Oncology
Vice Chair for Clinical Research and Director of the Gynecologic Cancer Immunotherapy Program Department of Gynecologic Oncology & Reproductive Medicine University of Texas MD Anderson Cancer Center Vice chair for clinical research
Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Jazaeri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2000 - 2004
University of Virginia Medical CenterResidency, Obstetrics and Gynecology, 1996 - 2000
University of Virginia School of MedicineClass of 1996
Certifications & Licensure
FL State Medical License 2024 - Present
AZ State Medical License 2024 - 2027
TN State Medical License 2024 - 2027
WA State Medical License 2024 - 2027
GA State Medical License 2024 - 2026
LA State Medical License 2024 - 2026
MS State Medical License 2024 - 2026
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
- Join now to see all
Clinical Trials
- Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer Start of enrollment: 2004 Jun 01
- Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2006 Apr 13
- Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery Start of enrollment: 2016 Nov 15
- Join now to see all
Publications & Presentations
PubMed
- Selective Alanine Transporter Utilization is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer.Hao Nie, Liping Liao, Rafal J Zielinski, Javier A Gomez, Akshay V Basi
Cancer Research. 2025-07-14 - PPP2R1A mutations portend improved survival after cancer immunotherapy.Yibo Dai, Anne Knisely, Mitsutake Yano, Minghao Dang, Emily M Hinchcliff
Nature. 2025-07-02 - Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics.Kari L Ring, Anne M Mills, Brooke E Howitt, Rachel N Grisham, Elizabeth D Euscher
Gynecologic Oncology. 2025-06-01
Lectures
- Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical c...2019 ASCO Annual Meeting - 6/1/2019
- A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or pe...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
New Houston Biotech Co. Developing Capsules for Hard-To-Treat TumorsJuly 9th, 2025- New Genetic Marker Linked to Improved Survival with Immunotherapy in Ovarian and Other CancersJuly 2nd, 2025
- HMN 2025: How New Genetic Marker Linked to Improved Survival with Immunotherapy in Ovarian and Different CancersJuly 2nd, 2025
- Join now to see all
Professional Memberships
- Member
- Fellow
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
